Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure
Shafiq U. Rehman, MD*,
Thomas Mueller, MD and
James L. Januzzi, Jr, MD, FACC*,*
* Cardiology Division and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 ST2 and Heart Failure Symptom Severity in Acute Heart Failure
Values of ST2 and association with symptom severity as a function of the New York Heart Association functional class.
|
|
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 ST2 Compared With Conventional Cardiac Biomarkers for Predicting Death
Receiver-operator characteristic curve analyses comparing ST2 to B-type natriuretic peptide (BNP), amino terminal B-type natriuretic peptide (NT-proBNP), and C-reactive protein (CRP) for predicting death at 1 year after acute heart failure.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Multimarker Testing and Rates of Death After Acute Heart Failure
Mortality rates among patients expressed as function of ST2 and (A) amino terminal B-type natriuretic peptide (NT-proBNP) or (B) B-type natriuretic peptide (BNP) concentrations.
|
|
|
